Fresenius Medical Care experienced a significant share price decline during Tuesday’s trading session, dropping 8.0% to €41.285 despite delivering financial results that surpassed analyst expectations. The dialysis provider opened the day at €41.16 before falling to a low of €40.555, a sharp reversal from the prior closing price of €44.86.
The company’s second-quarter operating income, excluding special items, reached €569 million, representing a 23% increase on a currency-adjusted basis and exceeding the market consensus estimate of €515 million. Revenue similarly topped forecasts, reaching €4.861 billion compared with expected levels of approximately €4.792 billion. These stronger-than-anticipated results reflected the benefits of cost-saving initiatives and favorable U.S. reimbursement rates.
Despite the solid financial performance, market sentiment turned negative as investors focused on underlying operational trends. Notably, Fresenius Medical Care reported a 0.9% year-over-year decline in comparable same-market treatment volumes in the United States, its largest market. Analysts identified this contraction as the most significant takeaway from the earnings report, raising concerns about future growth sustainability.
Management’s decision to reaffirm rather than raise its full-year guidance further disappointed investors. JPMorgan analyst David Adlington maintained an “Underweight” rating with a €37.40 price target, suggesting that the unchanged outlook could prompt analysts to reduce second-half earnings forecasts. Jefferies analyst James Vane-Tempest similarly retained an “Underperform” recommendation and €31 price target, citing weaker U.S. treatment volumes as the primary concern. The shares ranked among the weakest performers in the DAX during the session, with broader U.S. indices posting only modest gains.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI